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The p38 MAPK mediates transcriptional and post-
transcriptional control of cyclooxygenase-2 (COX-2) mRNA
following interleukin-1(IL-1)/lipopolysaccharide cellular
activation. We explored a positive feedback, prostaglandin
E2 (PGE2)-dependent stabilization of COX-2 mRNA medi-
ated by the p38 MAPK cascade in IL-1-stimulated human
synovial fibroblasts. We observed a rapid (5 min), massive
(>30-fold), and sustained (>48 h) increase in COX-2 mRNA,
protein, and PGE2 release following a recombinant human
(rh) IL-1 signal that was inhibited by NS-398, a COX-2
inhibitor, and SB202190, a selective, cell-permeable p38
MAPK inhibitor. PGE2 completely reversed NS-398-medi-
ated inhibition but not SB202190-dependent inhibition. The
eicosanoid didn’t potentiate IL-1-induced COX-2 expres-
sion nor did it activate COX-2 gene expression in quiescent
cells. Transfection experiments with a human COX-2 pro-
moter construct revealed a minor element of p38 MAPK-de-
pendent transcriptional control after IL-1 stimulation. p38
MAPK synergized with the cAMP/cAMP-dependent protein
kinase cascade to transactivate the COX-2 promoter. When
human synovial fibroblasts were activated with rhIL-1 for
3–4 h (steady state) followed by washout, the elevated levels
of COX-2 mRNA declined rapidly (<2 h) to control levels. If
PGE2, unlike EP2/3 agonists butaprost and sulprostone,
was added to fresh medium, COX-2 mRNA levels remained
elevated for up to 16 h. SB202190 or anti-PGE2 monoclonal
antibody compromised the stabilization of COX-2 mRNA by
PGE2. Deletion analysis using transfected chimeric lucifer-
ase-COX-2 mRNA 3-untranslated region reporter con-
structs revealed that IL-1 increased reporter gene mRNA
stability and translation via AU-containing distal regions of
the untranslated region. This response was mediated en-
tirely by a PGE2/p38 MAPK-dependent process. We con-
clude that the magnitude and duration of the induction of
COX-2 mRNA, protein, and PGE2 release by rhIL-1 is pri-
marily the result of PGE2-dependent stabilization of COX-2
mRNA and stimulation of translation, a process involving a
positive feedback loop mediated by the EP4 receptor and
the downstream kinases p38 MAPK and, perhaps, cAMP-de-
pendent protein kinase.
Cellular activation by external proinflammatory stimuli re-
sults in, among other responses, increased phospholipid-de-
rived eicosanoid synthesis that is believed to play a cardinal
role in the etiopathogenesis of many immune and inflamma-
tory diseases (1, 2). Additionally, acting locally in an intracrine,
autocrine, or paracrine fashion, eicosanoids initiate and mod-
ulate cell and tissue responses involved in many physiological
processes affecting essentially all organ systems in the human
organism (3, 4). Although synthesized through the concerted
activity of multiple enzyme systems, the rate-limiting step in
the formation of prostanoids is the conversion of arachidonic
acid to prostaglandin H2 by cyclooxygenase (COX)
1 (5, 6). A
constitutive and inducible form of COX has been identified, and
x-ray crystallographic analyses suggest strongly that they are
monotopic, endoplasmic reticulum-associated homodimeric en-
zymes that possess heme-dependent peroxidase and cyclooxy-
genase activity (7). The constitutive COX-1 gene has been
ascribed a homeostatic function and indeed has a GC-rich
housekeeping promoter (8). In contrast, the COX-2 gene
(mRNAs 4.6 and 2.8 kb) is rapidly induced by tumor promoters,
growth factors, cytokines, and mitogens in many cell model
systems (9–11). It behaves much like an immediate-early gene,
and its regulation has been shown to occur at both transcrip-
tional and post-transcriptional levels (12–14). In this regard,
the COX-2 message has an extensive 3-UTR having at least
two distinct polyadenylation sites and 22 Shaw-Kamen 5-
AUUUn-A-3 motifs (11). The latter sequences are believed to
be associated with message instability, translational efficiency,
and rapid turnover (15, 16). Furthermore, sequence analysis of
the 5-flanking region has shown several potential transcrip-
tion regulatory sequences, including a TATA box, a c/EBP
motif, two AP-2 sites, 3 SP-1 sites, two NF-B sites, a CRE
motif, and an Ets-1 site (no AP-1 site) (11). Nevertheless, de-
spite this wealth of structural information, it is still not totally
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clear how the COX-2 gene is regulated transcriptionally by
external stimuli particularly in terms of the relevant signaling
pathways and the transcription factors acting on 5-flanking
sequences. Even less is known about post-transcriptional reg-
ulation, although it is apparently critical in determining the
amplitude and duration of the inductive process.
Interleukin-1 (IL-1) occupies a prominent place in the hier-
archy of proinflammatory cytokines associated with inflamma-
tory, immune, and arthritic diseases. Indeed, there is now wide
agreement, based on animal models and clinical studies, that
the macrophage-derived cytokine plays a fundamental role in
the development of osteoarthritis (reviewed in Ref. 17). Among
the plethora of genes under IL-1 control, COX-2 is particularly
sensitive and is induced rapidly. In many cell types (e.g. syno-
vial fibroblasts (18) and endothelial cells (19)), IL-1 induces
COX-2 gene expression by binding to a specific cell-surface
receptor (IL-1RI) that has been shown to be the mammalian
homolog of the Drosophila Toll protein (20). The binding event
is followed by the activation of a signaling cascade involving
the adapter protein MyD88 that recruits IL-1R-associated ki-
nase and IL-1R-associated kinase 2 to the receptor complex.
The latter Ser/Thr kinases interact with the adapter molecule
TNF receptor-activated factor-6 that bridges them to the NF-
B-inducing kinase that in turn activates IB kinases  and 
(21–24). With the phosphorylation and degradation of IB,
NF-B is released to the nucleus and increases COX-2 pro-
moter activity (25, 26), although this has not been conclusively
shown in human synovial fibroblasts. In addition, c/EBP en-
hancer sequences are also believed to play a role and c/EBP/
synergize transcriptionally with NF-B for full activation of the
human COX-2 promoter (26, 27).
The p38 MAPKs (four isoforms) are members of the MAPK
family that are typically activated by environmental stresses
and pro-inflammatory cytokines (28). The signal is initiated by
membrane-proximal small GTPases of the Rho family, activa-
tion of an MAPKKK (e.g. MEKK1 and MLK), and phosphoryl-
ation and activation of an MAPKK (e.g. MKK3/6 or MEK3/6)
that in turn phosphorylates and activates p38 kinase (29, 30).
p38 kinase can phosphorylate trans-acting factors like ATF-2
and CREB-1 that render them transcriptionally competent
(31, 32). An alternative but perhaps less well appreciated
mechanism for the mediation of IL-1 signaling is in fact the
modulation of p38 MAPK activity (33, 34). It was shown that
p38 not only mediates a transcriptional response, presum-
ably at the level of the COX-2 promoter, but also at the level
of COX-2 mRNA stability (14, 35, 36). Indeed, the strength
and duration of COX-2 expression was largely attributed to
the posttranscriptional regulatory phase in which a short
(123-nucleotide) fragment of the COX-2 3-UTR was neces-
sary and sufficient for the regulation of mRNA stability by a
p38/MAPKAPK-2/hsp 27 cascade (36). The latter nucleotide
sequence interacted with a protein identified as an AU-rich
element/poly(U)-binding factor I (36).
In the present study, we report that the magnitude and
duration of the induction of COX-2 mRNA, COX-2 protein, and
PGE2 release by rhIL-1 is primarily the result of PGE2-de-
pendent stabilization of COX-2 mRNA in primary cultures of
human synovial fibroblasts. In addition, PGE2 mitigates
COX-2 mRNA decay and inhibition of COX-2 protein transla-
tion normally mediated by the 3-UTR region of COX-2 mRNA.
Finally, we provide evidence that the stabilization process
involves a positive feedback loop and is mediated by PGE2-
dependent up-regulation of the p38 MAPK cascade via the
prostaglandin EP4 receptor.
EXPERIMENTAL PROCEDURES
Chemicals—N-[2-(Cyclohexyloxy)-4-nitrophenyl)-methanesulfonamide]
(NS-398), nimesulide, N-[4-nitro-2-phenoxyphenyl)-methanesulfon-
amide], indomethacin 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-
indole-3-acetic acid, prostaglandin E2, 15-deoxy-
12,14-prostaglandin
J2, prostaglandin D2, leukotriene B4, butaprost, and the anti-PGE2
monoclonal anti-body were purchased from Cayman Chemical (Ann
Arbor, MI). Crystalline dexamethasone (9-fluoro-11,17,21-trihydroxy-
16-methylpregna-1,4-diene-3,20-dione), sodium fluoride, okadaic acid,
leupeptin, aprotinin, pepstatin, pyrrolidinedithiocarbamate, phenyl-
methylsulfonyl fluoride, actinomycin D, dithiothreitol, and bovine se-
rum albumin were products of Sigma. Verapamil, nifedipine, PD98059,
SB202190, KT-5720, and rolipram were purchased from Calbiochem,
and Bay 11-7082 was from Biomol (Plymouth Meeting, PA). SDS, ac-
rylamide, bisacrylamide, ammonium persulfate, and Bio-Rad protein
reagent originated from Bio-Rad. Tris base, EDTA, MgCl2, CaCl2, chlo-
roform, dimethyl sulfoxide (Me2SO), anhydrous ethanol (95%), metha-
nol (99%), formaldehyde, and formamide were obtained from Fisher.
Human recombinant IL-1 (rhIL-1) and recombinant human tumor
necrosis factor- (TNF-) were purchased from Genzyme Corp. (Cam-
bridge, MA). Dulbecco’s modified Eagle’s medium (DMEM), phosphate-
free and phenol-red free DMEM, Trizol reagent, heat-inactivated fetal
bovine serum, and an antibiotic mixture (10,000 units of penicillin
(base), 10,000 g of streptomycin (base)) were products of Life
Technologies, Inc.
Specimen Selection and Synovial Fibroblast Cultures—Synovial lin-
ing cells (human synovial fibroblasts, HSF) were isolated from synovial
membranes (synovia) obtained at necropsy from donors with no history
of arthritic disease (mean age 30  27). Additional experiments were
conducted with synovia from osteoarthritic (OA) and rheumatoid ar-
thritic (RA) patients undergoing arthroplasty who were diagnosed
based on the criteria developed by the American College of Rheumatol-
ogy Diagnostic Subcommittee for OA/RA (mean age 67  19). Human
synovial fibroblasts were released by sequential enzymatic digestion
with 1 mg/ml Pronase (Roche Molecular Biochemicals) for 1 h, followed
by 6 h with 2 mg/ml collagenase (type IA, Sigma) at 37 °C in DMEM
supplemented with 10% heat-inactivated FCS, 100 units/ml penicillin,
and 100 g/ml streptomycin (37, 38). Released HSF were incubated for
1 h at 37 °C in tissue culture flasks (Primaria 3824, Falcon, Lincoln
Park, NJ) allowing the adherence of nonfibroblastic cells possibly pres-
ent in the synovial preparation, particularly from OA and RA synovia.
In addition, flow cytometric analysis (Epic II, Coulter, Miami, FL),
using the anti-CD14 (fluorescein isothiocyanate) antibody, was con-
ducted to confirm that no monocytes/macrophages were present in the
synoviocyte preparation (38, 39). The cells were seeded in tissue culture
flasks and cultured until confluence in DMEM supplemented with 10%
FCS and antibiotics at 37 °C in a humidified atmosphere of 5% CO2,
95% air. The cells were incubated in fresh medium containing 0.5–1%
fetal bovine serum for 24 h before the experiments, and only second or
third passaged HSF were used.
Preparation of Cell Extracts and Western Blotting—50–100 g of
cellular extract (in RIPA buffer; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml each of
aprotinin, leupeptin, and pepstatin, 1% Nonidet P-40, 1 mM sodium
orthovanadate, and 1 mM NaF) from control and treated HSF were
subjected to SDS-polyacrylamide gel electrophoresis through 10% gels
(final concentration of acrylamide), under reducing conditions, and
transferred onto nitrocellulose membranes (Amersham Pharmacia Bio-
tech). Following blocking with 5% BLOTTO for 2 h at room temperature
and washing, the membranes were incubated overnight at 4 °C with
polyclonal anti-human COX-2 (Cayman Chemical Co., Ann Arbor, MI,
1:7500 dilution) in TTBS containing 0.25% BLOTTO. The second
anti-rabbit antibody-horseradish peroxidase conjugate (1:4000 dilu-
tion) was subsequently incubated with membranes for 1 h at room
temperature, washed extensively for 30–40 min with TTBS, and a
final rinse with TBS at room temperature. Following incubation with
an ECL chemiluminescence reagent (Amersham Pharmacia Biotech),
membranes were prepared for autoradiography, exposed to Kodak
X-Omat film, and subjected to digital imaging system (Alpha
G-Imager 2000; Canberra Packard Canada, Mississauga, Ontario,
Canada) for semi-quantitative measurements. In addition to the anti-
COX-2 antiserum, the following polyclonal antibodies were used:
total and anti-phospho-p38 MAP kinase (Thr-180/Tyr-182), anti-
phospho-ATF-2 (Thr-69/Thr-71), anti-phospho-c-Jun (Ser-63), and
anti-phospho-JNK/SAPK (Thr-183/Tyr-85).
Northern Blot Analysis of mRNA—Total cellular RNA was isolated
(1  106 cells  10–20 g of RNA) using the Trizol (Life Technologies,
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Inc.) reagent. Generally, 5 g of total RNA were resolved on 1.2%
agarose-formaldehyde gel and transferred electrophoretically (30 V
overnight at 4 °C) to Hybond-N nylon membranes (Amersham Phar-
macia Biotech) in 0.5 Tris/acetate/EDTA (TAE) buffer, pH 7. After
prehybridization for 24 h, hybridizations were carried out at 50 °C for
24–36 h, followed by high stringency washing at 68 °C in 0.1 SSC,
0.1% SDS. The following probes, labeled with digoxigenin (DIG)-dUTP
by random priming, were used for hybridization. Human COX-2 cDNA
(1.8 kb, Cayman Chemical Co.) was cloned into the EcoRV site of
pcDNA 1 (Invitrogen, Carlsbad, CA) and released by PstI and XhoI
digestion; a 780-bp PstI/XbaI fragment was obtained from GAPDH
cDNA (1.2 kb; American Type Culture Collection, Manassas, VA). This
latter probe served as a control of RNA loading as GAPDH is constitu-
tively expressed. All blots were subjected to a digital imaging system
(Alpha G-Imager 2000; Canberra Packard Canada, Mississauga, On-
tario, Canada) for semi-quantitative measurements, and changes in
COX-2 expression were always considered as a ratio, COX-2/GAPDH
mRNA.
Transfection Experiments—Transient transfection experiments were
conducted in 4-, 6-, or 12-well cluster plates with HSF as described
previously (37). Transfections were conducted using the FuGene 6
(Roche Molecular Biochemicals) or LipofectAMINE 2000 reagents
(Life Technologies, Inc.) method for 6 h according to the manufacturer’s
protocol with cells at around 40–50% confluence. HSF were re-exposed
to a culture medium  1% FCS for 2 h prior to the addition of the
biological effectors. Transfection efficiencies were controlled by co-
transfection with 0.5 g of pCMV--gal, a -galactosidase reporter
vector under the control of cytomegalovirus promoter. The COX-2 pro-
moter (2390 to  34)-LUC plasmid was kindly provided by Dr. Ste-
phen Prescott, University of Utah (40), as were the chimeric luciferase
reporter plasmids fused with the entire human COX-2 mRNA 3-UTR
(1451 bp), AU-rich elements (429 bp of which the first 116 bp contain an
AU cluster) or a construct completely devoid of the COX-2 3-UTR but
containing the SV40 poly(A) signal (41). The plasmids are designated
LUC-3-UTR, LUC-ARE, LUC-3-UTR. The p38 MAPK kinase
(MEK3/MKK3) and pFCPKAcat expression vectors was purchased from
Stratagene (La Jolla, CA). Luciferase values, expressed as relative light
units, were normalized to 1 OD unit of -galactosidase activity and
protein content per sample for all experiments.
RT-PCR for Luciferase and GAPDH—The oligonucleotide primers
for the polymerase chain reactions (PCR) were prepared with the aid of
a DNA synthesizer (Cyclone model, Biosearch Inc., Montreal, Quebec,
Canada) and used at a final concentration of 200 nmol/liter. The se-
quences for the luciferase primers are as follows: 5-ACGGATTAC-
CAGGGATTTCAGTC-3 and 5-AGGCTCCTCAGAAACAGCTCTTC-3
(antisense) for the luciferase fragment of 367 bp (41). The sequences for
the GAPDH (which served as a standard of quantitation) primers are
5-CAGAACATCATCCCTGCCTCT-3, which corresponds to position
604–624 bp of the published sequence, and 5-GCTTGACAAAGTG-
GTCGTTGAG-3, from position 901–922 bp, for an amplified product of
318 bp (37). Two g of total RNA, extracted with the Trizol reagent, was
reverse-transcribed and then subjected to PCR as described previously
(37). RT and PCR assays were carried out with the enzymes and
reagents of the GeneAmP RNA PCR kit manufactured by PerkinElmer
Life Sciences. Both the RT and PCRs were done in a Gene ATAQ
Controller (Amersham Pharmacia Biotech).
The amplification process was conducted over 10–30 cycles in order
to define the linear range of product amplification; the first cycle con-
sisted of a denaturation step at 95 °C for 1 min, followed by annealing
and elongation at 60 °C for 30 s and 72 °C for 1.5 min, respectively. All
subsequent cycles were executed under the same conditions, with the
exception of the last cycle, where the elongation step was extended to 7
min. We found a linear range (log luciferase/GAPDH versus log cycle
number) between 10–17; as such we chose 11–13 cycles depending on
the type of experiment.
The PCR products were analyzed and verified by electrophoresis on
1.15% agarose gels in a Tris borate/EDTA buffer system as described
previously (37). All gel photos were subjected to a digital imaging
system (see above) for semi-quantitative measurements, and results
were expressed as a ratio of luciferase/GAPDH PCR fragments.
Extraction of Nuclear Proteins and Electrophoretic Mobility Shift
Assay Experiments—Confluent HSF in 4-well cluster plates (3–5  106
cells/well) from control and treated cells were carefully scraped into 1.5
ml of ice-cold phosphate-buffered saline and pelleted by brief centrifu-
gation. Nuclear extracts were prepared as described previously (37).
Double-stranded oligonucleotides containing consensus and mutant
sequences were from Geneka Biotechnology Inc. (Montreal, Quebec,
Canada) and were end-labeled with [-32P]ATP using T4 polynucleotide
kinase (Promega, Madison, WI). The sense sequences of the oligos
tested are as follows: NF-B p50, 5-GCC ATG GGG GGA TCC CCG
AAG TCC-3; NF-B p50 mut, 5-GCC ATG GGC CGA TCC CCG AAG
TCC-3; ATF-2, 5-GAT TCA ATG ACA TCA CGG CTG TG-3; ATF-2
mut, 5-GAT TAC AGA ACA TAG CGG CTG TG-3. Binding buffer
consisted of 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM dithiothreitol,
0.5 mM EDTA, 1 mM MgCl2, 4% glycerol, and 2.5 g of poly(dI-dC).
Binding reactions were conducted with 15 g of nuclear extract and
100,000 cpm of 32P-labeled oligonucleotide probe at 22 °C for 20 min in
a final volume of 10 l. Binding complexes were resolved by nondena-
turing polyacrylamide gel electrophoresis through 6% gels in a Tris
borate buffer system, after which the gels were fixed, dried, and pre-
pared for autoradiography.
Eicosanoid Enzyme-linked Immunosorbent Assay (ELISA)—Meas-
urements of the principal eicosanoids produced by HSF were performed
by ELISA kits according to the manufacturer’s instructions (R & D
Systems, Minneapolis, MN). Detection limits for PGE2, LTB4, and
PGD2 were 39, 3.9, and 7.8 pg/ml, respectively.
RESULTS
Kinetic Paradigm of rhIL-1 Induction of COX-2 Gene in
HSF—Studies in our laboratory (39) indicate that the EC50 for
rhIL-1-dependent COX-2 gene induction in our cell culture
system is 5.7 pmol/liter or 100 pg/ml. As such, this concentra-
tion was chosen for all subsequent experimentation. Time
course studies revealed that increases in COX-2 mRNA expres-
sion were detectable within 5 min (1.4-fold), reached greater
than 10-fold after 1 h, attained steady state at 3–4 h, and
thereafter declined very gradually for the next 44 h as shown in
Fig. 1, A and B. The COX-2 protein was perceptible within 1 h
following stimulation with rhIL-1 and thereafter followed a
pattern of biosynthesis closely resembling COX-2 mRNA ex-
pression (Fig. 1C). The rhIL-1-stimulated PGE2 release pro-
file is also illustrated in Fig. 1D (mean, n  4). The eicosanoid
levels reached 21 ng per 106 cells after 1 h and 130 ng by 4 h,
and by 24 h we detected more than 6000 ng per 106 cells. Other
arachidonic acid metabolites elaborated by HSF, such as PGD2
and LTB4, were also released in higher concentrations after
IL-1-stimulation; however, in both cases, the amounts de-
tected approximated 200 pg/ml per 106 cells (data not shown).
Suppression of rhIL--induced COX-2 Gene Expression by
COX Inhibitors, Role of PGE2—We reported (39) that the
COX-2 preferential inhibitor NS-398 and its structural analog
nimesulide inhibit rhIL-1-induced COX-2 mRNA expression
(maximum80%), COX-2 protein synthesis (maximum80%),
and PGE2 release (maximum 95%) in a dose-dependent man-
ner. The concentrations used represent sub- and therapeutic
concentrations. In the present study, when PGE2 was added to
the incubation medium in increasing concentrations along with
NS-398 and rhIL-1, the inhibitory effect of NS-398 on COX-2
mRNA and protein synthesis was completely reversed (Fig. 2, A
and B); PGE2 didn’t potentiate the inductive effect of rhIL-1
(Fig. 2A).
It is widely acknowledged that IL-1 and tumor necrosis
factor- (TNF-) have overlapping proinflammatory effects,
activate common signaling cascades, and induce similar target
genes (reviewed in Ref. 42). As such we wondered whether
TNF- would also require PGE2 to mediate the induction of
COX-2. Previously, we showed that TNF-, at physiologically
relevant levels (e.g. 1–10 ng/ml or 60–60 pmol/liter), induces
COX-2 mRNA expression, COX-2 protein synthesis, and PGE2
release in HSF (43); here we demonstrate that the induction
was not abrogated with the addition of NS-398, and in fact the
inductive effect was potentiated with the addition of increasing
concentrations of PGE2 (Fig. 2C). In carefully controlled com-
parisons of IL-1 versus TNF- stimulation of COX-2 expres-
sion and PGE2 release in our cell culture system, we observed
that IL-1 is at least 15-fold more potent in terms of COX-2
mRNA expression (ratio 19 to 1 COX-2 mRNA normalized to
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GAPDH, n  3) and more than 40 times more active with
respect to PGE2 release (6.5 g of PGE2/10
6 cells/24 h versus
0.159 g of PGE2/10
6 cells/24 h, n  3).
Interestingly, the inflammatory 5-lipoxygenase product
LTB4 could also reverse NS-398-dependent inhibition of IL-1-
induced COX-2 mRNA expression and protein synthesis,
whereas a putative anti-inflammatory prostanoid and PPAR
agonist 15-deoxy-12,14-prostaglandin J2, had no effect (Fig. 3).
All three arachidonic acid metabolites had absolutely no effect
on the COX-2 gene in quiescent, unstimulated cells. The non-
selective COX-2 inhibitor indomethacin (0.5–5 g/ml) also in-
hibited rhIL-1-induced COX-2 mRNA expression (maximum
80%) and COX-2 protein synthesis (maximum 80%) but in
an inverse, dose-dependent manner (Fig. 3). As expected, PGE2
release was blocked by at least 95% at 5 g/ml (data not
shown).
p38 MAP Kinase Activity and PGE2-dependent Regulation of
COX-2 Gene Expression in IL-1-treated Cells—Previous stud-
ies in our laboratory demonstrate that calcium channel block-
ers (e.g. verapamil and nifedipine) and reactive oxygen species
scavengers (e.g. pyrrolidinedithiocarbamate, N-acetyl-L-cys-
teine, and L-N6-(1-iminoethyl)lysine) exert either no effect or
very modest inhibition on rhIL-1-stimulated COX-2 mRNA
and protein synthesis (39). In this study, SB202190 (SAPK/
p38 inhibitor) suppressed rhIL-1-induced COX-2 mRNA and
protein synthesis by 80% (78  9%, mean  S.D., n  7) (Fig.
4, A and B); PGE2 release was suppressed by greater than 95%
(data not shown). The MEK1/2 inhibitor PD98059, and the IB
kinase inhibitor, Bay-11-7802 were without significant effect,
whereas the PKA inhibitor KT-5720 had modest but consistent
inhibitory activity. In order to determine whether the suppres-
sive effect of SB202190 was also dependent on PGE2 release (as
in Fig. 2, A and B), we co-incubated 10–1000 nmol/liter of PGE2
with SB202190 and rhIL-1 and found that the eicosanoid
restored about 20–25% (23.08  2.92%, mean  S.D., n  7) of
the levels observed with rhIL-1 alone (Fig. 4C). As such, these
FIG. 1. Time course of rhIL-1 stim-
ulation of COX-2 mRNA (A and B),
COX-2 protein (C), and PGE2 release
(D). Cultured confluent human synovial
fibroblasts (HSF, 1.2  106 cells in 6-well
cluster plates) were preincubated for 24 h
in DMEM supplemented with 1% FCS
plus antibiotics at 37 °C in order to en-
sure synchrony and quiescence. Cells
were then treated for varying times (0–48
h) with 5.7 pmol/liter (100 pg/ml) of rhIL-
1. Monolayers were extracted for protein
or RNA; 50 g of protein were analyzed
for COX-2 protein by Western blotting us-
ing a specific polyclonal anti-COX-2 anti-
serum, whereas 5 g of total RNA were
analyzed for COX-2 mRNA by Northern
hybridization using a specific DIG-labeled
cDNA probe as described under “Experi-
mental Procedures.” Conditioned medium
was collected and analyzed by ELISA for
PGE2. Results are expressed as the mean
of 4 separate experiments performed in
duplicate. Interassay coefficient of varia-
tion never exceeded 13% when expressed
as ng/106 cells.
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results suggested that part of PGE2-dependent effect (compare
Fig. 2, A and B with Fig. 4, A–C) was not affected by the
presence of SB202190 (i.e. not p38 MAP kinase-dependent). As
such we investigated the cAMP/PKA signaling cascade, which
is also potently stimulated by PGE2 via the prostaglandin EP4
receptor in our cell cultures (44, 45). We co-incubated the cAMP
mimetics rolipram, a cAMP-dependent phosphodiesterase type
IV inhibitor, and forskolin, an activator of adenylate cyclase,
with SB202190 in order to examine the role of the cAMP
signaling cascade of COX-2 mRNA stability. The levels of
COX-2 mRNA were reactive to elevations in cellular cAMP and
were restored to about 15% (15.05  1.83%, mean  S.D., n 
7) of the rhIL-1-induced levels in the face of p38 MAP kinase
blockade (Fig. 4D).
The activation by pro-inflammatory cytokines of the p38
kinase cascade is well described, although the role of prosta-
noids in this regard is not clear (reviewed in Ref. 28). In HSF,
the stimulation of p38 kinase phosphorylation by rhIL-1 was
bi-phasic, reaching a maximum level at 20 min, a rapid decline
to near control values between 20 and 60 min, followed by a
second surge with a zenith at 4 h (Fig. 5A). The initial phase
was unaffected by co-incubations with NS-398, whereas the
second phase was abolished suggesting that the latter phase of
p38 phosphorylation was PGE2-dependent. Surprisingly,
rhIL-1 didn’t activate the phosphorylation of another stress-
activated kinase, JNK1/2 in our cell cultures to any significant
extent (data not shown), in contrast to what we observed in
human chondrocytes.2 PGE2 (100 ng/ml) caused a robust and
protracted phosphorylation of p38 kinase that persisted for up
to 16 h (Fig. 5A); PGE2 didn’t phosphorylate JNK1/2 apprecia-
bly (data not shown). These findings are consistent with our
previous work showing PGE2-dependent stimulation of
MEK3/6, ATF-2, and CREB/ATF-1 phosphorylation in an iden-
tical time frame (46).
Gel-shift analysis revealed that SB202190 (500 nmol/liter to
10 mol/liter) inhibited rhIL-1-induced ATF-2 oligonucleotide
binding but caused a mild induction of NF-B (p50) nuclear
binding proteins both in the absence and presence of IL-1
(data not shown).
In order to examine for elements of transcriptional control of
COX-2 via p38 MAP kinase or cAMP/PKA signaling, we con-
ducted transient transfection analyses and observed that
rhIL-1 (100 pg/ml) stimulated a human COX-2 promoter-
luciferase reporter construct by 1.99  0.14-fold (mean  S.D.,
n  4); this induction was not inhibited by NS-398 nor PGE2
but was completely abrogated by SB202190 (Fig. 5B). Neither
NS-398, PGE2, nor SB202190 had any effect on basal promoter
activity. In companion experiments, co-expression of a MEK3
expression vector stimulated the COX-2 promoter luciferase
construct by 1.76  0.23-fold (mean  S.D., n  4); SB202190
abolished the induction completely (Fig. 5B). The magnitude of
COX-2 promoter activation by rhIL-1 and MEK3 was not
significantly different. The overexpression of catalytic subunits
of PKA had no effect on the COX-2 promoter activity (Fig. 5B),
whereas co-expression of MEK3 and PKAcat synergized to in-
crease COX-2 promoter activity to 3.26  0.33-fold (mean 
S.D., n 4), an effect partially inhibited by SB202190 (Fig. 5B).
Prostaglandin E2 Stabilizes COX-2 mRNA—Judging by the
2 W. H. Faour, Y. He, Q. W. He, M. de Ladurantaye, M. Quintero, A.
Mancini, and J. A. Di Battista, unpublished observations.
FIG. 2. rhIL-1 stimulation of COX-2 mRNA (A) and COX-2
protein (B) is PGE2-dependent. TNF- stimulation of COX-2 mRNA
is PGE2-independent (C). Quiescent HSF were treated with 100 pg/ml
(5.7 pmol/liter) of rhIL-1 (A and B) or 10 ng/ml of TNF- (C) for 16 h
with or without NS-398 (100 nmol/liter) in the absence or presence of
increasing concentrations of PGE2 (10 pmol/liter to 1 mol/liter, log
M, 11 to 6, as per figure). Monolayers were extracted for protein or
RNA and prepared for Western and Northern blotting as described
under “Experimental Procedures.” Blots are representative of three
separate experiments that gave essentially identical results.
FIG. 3. Effect of HSF eicosanoids on basal and IL-1-stimu-
lated COX-2 mRNA and COX-2 protein. Quiescent HSF were
treated with vehicle (lane 1) or with 100 pg/ml (5.7 pmol/liter) of
rhIL-1 (lane 2) for 16 h with NS-398 (100 nmol/liter) (lanes 3–6) in the
presence of PGE2 (E2, 100 nmol/liter), 15-deoxy-
12,14-prostaglandin J2
(J2, 100 nmol/liter), or leukotriene B4 (B4, 100 nmol/liter) (lanes 4–6).
In lanes 7–9, cells were treated with PGE2 (E2, 100 nmol/liter), 15-
deoxy-12,14-prostaglandin J2 (J2, 100 nmol/liter) or leukotriene B4 (B4,
100 nmol/liter) alone. In lanes 10–12, cells were co-incubated with 100
pg/ml of rhIL-1 and 0.5, 1, or 5 g/ml of indomethacin (Indo). Mono-
layers were extracted for protein or RNA and prepared for Western and
Northern blotting as described under “Experimental Procedures.”
COX-2 mRNA, upper panel; COX-2 protein, lower panel.
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accumulated data (see above), it is unlikely that PGE2 modifies
COX-2 expression in HSF at the transcriptional level. As such
we examined post-transcriptional mechanisms involving
strictly message stabilization and/or protein translation. As a
first approach we employed classical techniques involving
measuring COX-2 mRNA in transcriptionally arrested cells
FIG. 4. Effect of protein kinase inhibitors on rhIL-1 stimulation of COX-2 mRNA (A) and COX-2 protein (B). Possible mediation by
p38 MAP kinase and protein kinase A (C and D). Quiescent HSF were treated with vehicle (c, lane 1) or with 100 pg/ml (5.7 pmol/liter) of rhIL-1
(lane 2) for 16 h in the presence of either PD98059 (PD, 50 mol/liter), a MEK1/2 inhibitor, SB202190 (SB, 10 mol/liter), a p38 MAP kinase
inhibitor, or KT-5720 (KT, 2 mol/liter), a PKA inhibitor, NS-398 (NS, 100 nmol/liter), or Bay-11–7082 (BY, 5 mol/liter), an IKK inhibitor.
Monolayers were extracted for protein or RNA; 5 g of total RNA were analyzed for COX-2 mRNA and GAPDH mRNA by Northern hybridization
using specific DIG-labeled cDNA probes, whereas 50 g of protein were analyzed for COX-2 protein by Western blotting using a specific polyclonal
anti-COX-2 antiserum as described under “Experimental Procedures.” C and D, cells were incubated with rhIL-1 in presence of SB202190 in the
absence or presence of increasing concentrations of PGE2 (E2, 0.01–1 mol/liter) or the cAMP mimetics forskolin (20–60 mol/liter)  rolipram
(100 mol/liter) as per the figure. Northern analysis was performed as described above. C, *p 	 0.01; D, **p 	 0.04, Student’s t test.
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(actinomycin D) in the absence or presence of PGE2. When HSF
were activated with rhIL-1 for 3–4 h (steady state) followed
by washout and a fresh change of medium, the elevated levels
of COX-2 mRNA declined rapidly (t1⁄2  0.85 h, n  4 determi-
nations) such that within 2 h the levels were similar to control,
unstimulated cells (Fig. 6, A and B). The inclusion/exclusion of
actinomycin D (1 g/ml) had no effect on the rate of COX-2
mRNA decay in these experiments (data not shown). However,
if PGE2 (1 g/ml) was added to fresh medium (in the presence
of actinomycin D) COX-2 mRNA levels remained elevated for
up to 16 h (t1⁄2  13.02 h, n  4 determinations) and declined
thereafter (Fig. 6, A and B). The addition of a monoclonal
anti-PGE2 antibody, but not a monoclonal anti-LTB4 antibody
(control), abolished the stabilizing effect suggesting the exog-
enously added PGE2 alone was responsible for stabilizing
COX-2 mRNA. Although we showed that long term phospho-
rylation of p38 kinase by IL-1 was PGE2-dependent (see Fig.
5A), it was necessary to establish whether COX-2 mRNA sta-
bilization by PGE2 was also a p38 kinase-mediated process.
Indeed, SB202190 reduced considerably the stabilization of
COX-2 mRNA by PGE2 (Fig. 6, C and D), whereas the PKA
inhibitor KT-5720 was somewhat effective in this regard
(14.21  3.39%, n  4).
As we have shown (45), HSF express trace quantities of EP3
receptors (isotype I) that mediate either calcium fluxes or de-
creases in cellular levels of cAMP. The predominant EP4 re-
ceptor is associated with increases in cellular cAMP levels
(44–46) and is coupled to MAP kinase cascades by Rap1/B-Raf
activation (reviewed in Ref. 47). Butaprost (EP2 
 P3 agonist)
and sulprostone (EP1 
 EP3 agonist) (data not shown) had
little stabilizing effect on COX-2 mRNA up to 10 mol/liter
(Fig. 6E, compare PGE2 versus butaprost).
FIG. 5. A, time course of p38 MAP kinase
phosphorylation (Thr-80/Tyr-82) by
rhIL-1 and PGE2. Quiescent HSF treated
for varying times (0–16 h, 16C  16 h
control) with 100 pg/ml (5.7 pmol/liter) of
rhIL-1 (top panel), rhIL-1NS-398 (100
nmol/liter) (middle panel), or PGE2 (100
nmol/liter) (lower panel). Monolayers were
extracted for protein, and 50 g were ana-
lyzed for total and phospho-p38 MAP ki-
nase by Western blotting using a specific
rabbit polyclonal antisera as described
under “Experimental Procedures.” B, tran-
scriptional activation of the COX-2 pro-
moter by IL-1 and the role of p38 MAP
kinase. Cells were plated at 40% conflu-
ence in DMEM supplemented with 10%
heat-inactivated FCS, 100 units/ml penicil-
lin, and 100 g/ml streptomycin. Two g of
the COX-2 promoter-luciferase construct,
in the presence or absence of 50 ng each
of pFCMEK3, pCMV, or pFCPKAcat, or
pFCMEK3  pFCPKAcat and 0.5 g of
pCMV--galactosidase were transfected for
6 h using LipofectAMINE 2000 according
to the manufacturer’s instructions. Follow-
ing a change in medium containing 1%
FCS (2 h), transfected cells were incubated
for 6 h with biological effectors rhIL-1 (5.7
pmol/liter), NS-398 (100 nmol/liter),
SB202190 (10 mol/liter), and PGE2 (100
nmol/liter) as per the figure. Cells were
lysed, and the luciferase activity, -galac-
tosidase activity, and protein content were
determined as described under “Experi-
mental Procedures.” *, p 	 0.005 versus
control; , p 	 0.01 versus IL-1; , p 	
0.01 versus pFCMEK3; p 	 0.05 versus
pFCMEK3  pFCPKAcat (mean  S.D.,
n  8 determinations in duplicate).
PGE2 Regulates COX-2 mRNA Stability and Translation31726
As mentioned earlier, the COX-2 mRNA has multiple copies
of the Shaw-Kamen AU-rich sequences that are believed to
influence message stability. Recent studies (36, 41) have pro-
vided evidence that the AU-rich elements (6) in the first 116 bp
of the 3-UTR may mediate COX-2 mRNA instability. Further-
more, specific cytoplasmic AU-binding proteins were identified
that may initiate message degradation (36, 41). To determine
whether PGE2/p38 MAP kinase-dependent mRNA stabilization
is manifested through the 3-UTR and AU-rich sequences, we
transfected HSF with cytomegalovirus-driven chimeric expres-
sion constructs containing luciferase cDNA (reporter) fused to
the COX-2- 3-UTR (Luc  3-UTR), AU-rich region (Luc 
ARE), or complete removal of the 3-UTR region (Luc 3UTR)
(kindly provided by Dr Stephen Prescott, University of Utah).
By using an identical experimental design as in Fig. 6A, we
observed that rhIL-1 stimulated luciferase mRNA after 4 h
stimulation by more than 3-fold using Luc 3-UTR constructs
(Fig. 7A, top, representative RT-PCR; lower panel, densitomet-
ric analysis of five determinations). Removal of the rhIL-1
stimulus for 2 h under washout conditions resulted in a sub-
stantial (apparently rapid) decrease in luciferase mRNA. The
addition of PGE2 reversed the dramatic fall in luciferase mRNA
levels, an effect largely reversed by the co-addition of the p38
kinase inhibitor SB202190. As expected, HSF transfected with
constructs devoid of COX-2 3-UTR were unresponsive to our
treatment protocols, whereas the inclusion of the AU-rich re-
gion of COX-2 3-UTR resulted in more modest effects on lucif-
erase mRNA expression. No major mRNA decay was observed
in the latter experiments for an additional 4 h, whereas the
presence of the entire 3-UTR region resulted in complete dis-
appearance of Luc mRNA under our experimental conditions
(data not shown). In addition, when we treated cells trans-
fected with the Luc  3-UTR construct followed by treatments
with IL-1 in the absence or presence of NS-398, with or
without PGE2, rhIL-1 substantially augmented luciferase
mRNA after 16 h of stimulation. The stimulation was abro-
gated by the addition of NS-398 to a substantial degree; the
latter inhibitory effect was entirely reversed by further addi-
tions of PGE2 (Fig. 7B).
PGE2 Mitigates the Inhibition of Protein Translation by 3-
UTR Region of COX-2 mRNA—There is now good evidence that
the AU-rich elements of certain cytokines and COX-2 mRNA
inhibit translation (41, 48–50). By using the same chimeric
constructs transiently transfected in our primary cultures of
HSF as described above, we found dramatically increased lu-
ciferase activity (protein) when the 3-UTR was removed (Luc
3UTR COX-2) as compared with Luc 3-UTR or Luc ARE
(Fig. 7C). The entire 3-UTR COX-2 region mediated the most
robust inhibition of translation with the AU-rich region (prox-
imal 116 bp) displaying intermediate inhibitory activity in this
regard (Fig. 7C). In order to assess whether translational
mechanisms are implicated in the induction of COX-2 protein
FIG. 6. PGE2-dependent stabilization of COX-2 mRNA is medi-
ated by p38 MAP kinase and protein kinase A. Quiescent HSFs
were treated with vehicle (c) or with 100 pg/ml (5.7 pmol/liter) of
rhIL-1 (I) for 4 h (steady state) after which time cells were washed out
(wo) and treated with actinomycin D (1 g/ml) for 30 min, and then
fresh medium was added containing either vehicle (wo) or PGE2 (E2,
100 nmol/liter). After an additional 2, 4, 8, or 16 h of incubation,
monolayers were extracted for RNA at each time point, and 5 g of total
RNA were analyzed for COX-2 mRNA and GAPDH mRNA by Northern
hybridization using specific DIG-labeled cDNA probes (A). B, densito-
metric analysis of COX-2 mRNA decay in the presence or absence of
PGE2 (n  4 determinations). C–E, cells were treated with vehicle (c) or
with 100 pg/ml (5.7 pmol/liter) of rhIL-1 (I) for 4 h, washed out (wo),
treated with actinomycin D (1 g/ml) for 30 min, and then fresh me-
dium was added containing either vehicle (wo) or PGE2 (E2, 100 nmol/
liter) alone or in the presence of increasing amounts of a monoclonal
anti-PGE2 antibody or, as a control, a monoclonal anti-LTB4 antibody
(C), SB202190 (SB, 10 mol/liter) or KT-5720 (KT, 2 mol/liter) (D), or
increasing concentrations of PGE2 (E2, 0.01–1 mol/liter) or butaprost
(BU, 0.1–10 mol/liter) (E) for 4 more hours.
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synthesis by IL-1 and whether the effect may be PGE2-de-
pendent, we transfected HSF with the chimeric constructs and
treated the cells with IL-1 in the absence or presence of
NS-398 with or without PGE2. Indeed rhIL-1 substantially
increased luciferase activity (protein synthesis) after 16 h of
stimulation, and the effect proved to be almost entirely PGE2-
dependent (compare data, rhIL-1NS-398 versus rhIL-
1NS-398PGE2, Fig. 7D). Interestingly, the AU-rich region
of COX-2 mRNA appeared to play a modest role in the PGE2-
dependent increase in protein synthesis with the distal
AUUUA sequences being apparently more important in this
regard (Fig. 7D).
DISCUSSION
Normally not expressed, the elevated levels of COX-2 mRNA,
COX-2 protein, and PGE2 release observed in OA/RA-affected
synovial membranes have been associated etiologically with
the disease process (17, 18). Thus understanding the mecha-
nisms responsible for aberrant COX-2 expression is of consid-
erable clinical concern. It now seems clear from published
evidence and the present study that the COX-2 gene is regu-
lated through both 5 (transcriptional) and 3 (post-transcrip-
tional) regulatory elements following IL-1 signal activation in
both normal (this study) and transformed cell phenotypes. We
believe that the levels of IL-1-induced COX-2 mRNA are the
FIG. 7. PGE2-dependent stabilization of COX-2 mRNA and increased translation is mediated by the proximal (AU-rich) and distal
portion of COX-2 3-UTR. Cells were plated at 40% confluence in DMEM supplemented with 10% heat-inactivated FCS, 100 units/ml penicillin,
and 100 g/ml streptomycin. Two g of LUC-3-UTR, LUC-ARE, or LUC-3-UTR and 0.5 g of pCMV--galactosidase were transfected for 6 h
using FuGene 6TM according to the manufacturer’s instructions. Following a change in medium containing 1% FCS (2 h), transfected cells were
treated with vehicle (control) or with 100 pg/ml (5.7 pmol/liter) of rhIL-1 for 4 h, washed out (wo), treated with actinomycin D (1 g/ml) for 30
min, and then fresh medium was added containing either vehicle (wo) or PGE2 (E2, 100 nmol/liter) alone or in the presence of SB202190 (SB, 10
mol/liter) for an additional 2 h (A). Monolayers were scraped into phosphate-buffered saline, divided into 2 portions, centrifuged, and extracted
for protein to determine -galactosidase activity or extracted for RNA, and 1 g of total RNA was analyzed for luciferase mRNA and GAPDH mRNA
by RT-PCR as described under “Experimental Procedures.” A representative RT-PCR gel is shown along with statistical analysis of densitometric
data (n  5). #, p 	 0.02 versus control LUC-3-UTR; *, p 	 0.0005 versus control LUC-3-UTR; **, p 	 0.0001 versus rhIL-1 LUC-3-UTR; ,
p 	 0.0002 versus rhIL-1 Wo (2 h) LUC-3-UTR; , p 	 0.001 versus rhIL-1  PGE2 (2 h) LUC-3-UTR. B, cells were incubated for 16 h with
rhIL-1 (100 pg/ml), rhIL-1  NS-398 (100 nmol/liter), or rhIL-1  NS-398 PGE2 (100 nmol/liter). Monolayers were extracted for RNA, and
1 g of total RNA was analyzed for luciferase mRNA and GAPDH mRNA by RT-PCR. C and D, 2 g of LUC-3-UTR, LUC-ARE, or LUC-3-UTR
and 0.5 g of pCMV--galactosidase were transfected for 6 h using FuGene 6TM followed by a change in medium containing 1% FCS (2 h). Cells
were then analyzed for luciferase activity (C) or incubated for 16 h with biological effectors rhIL-1 (100 pg/ml), rhIL-1NS-398 (100 nmol/liter),
or rhIL-1NS-398 PGE2 (100 nmol/liter) as per the figure (D). Cells were lysed and the luciferase activity, -galactosidase activity, and protein
content were determined as described under “Experimental Procedures.” n  3 determinations; *, p 	 0.01 versus LUC-3-UTR; **, p 	 0.001
versus LUC-3-UTR; , p 	 0.03 versus control; , p 	 0.001 versus control; #, p 	 0.01 versus rhIL-1; ##, p 	 0.001 versus rhIL-1; &, p 	
0.001 versus rhIL-1  NS-398; &&, p 	 0.001 versus rhIL-1  NS-398.
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result of a more minor element of transcriptional control sup-
ported by robust post-transcriptional regulation (i.e. message
stability and/or translational control). The COX-2 protein lev-
els always mirrored precisely COX-2 mRNA in our studies,
suggesting precise coordination between message expression
and translation. Our data confirm previous work (14, 35, 36)
implicating the p38 MAPK cascade as critical to the magnitude
and duration of cellular COX-2 mRNA. We now add, however,
that the COX-2 product, PGE2, is largely responsible for this
activation of p38 MAPK cascade resulting in the stabilization
of COX-2 mRNA and increased COX-2 protein synthesis. In
this regard, the exact contribution of the cAMP/PKA pathway
(see “Results”) will require further investigation but is likely to
be another example of signaling redundancy (51). In this con-
nection, our COX-2 promoter experiments seem to suggest that
p38 MAP kinase and the cAMP/PKA synergize to activate
transcription so that expression of the COX-2 gene may be
controlled transcriptionally and post-transcriptionally by the
latter two signaling pathways. The data are also consistent
with a positive feedback loop involving released PGE2 binding
to the prostaglandin EP4 receptor in our cell cultures. There-
fore, considering the impressive amounts of PGE2 released by
human OA/RA synovial membranes (in explant cultures (52)),
it is conceivable that the COX-2 gene expression levels are
sustained in this cyclic, positive-feedback loop.
There are contrary reports (53, 54) of PGE2 inhibiting IL-1-
induced COX-2 expression in human umbilical vein endothelial
cells presumably through a negative feedback loop. The design
of the latter studies was different to the extent that high
concentrations of exogenous PGE2 were added in co-incubation
with IL-1 and, in some cases, in the absence of any inhibition
of endogenous prostanoid production (e.g. by NS-398). One
explanation could be that added PGE2 inhibits IL-1-induced
NF-B-driven transactivation of the COX-2 promoter by inter-
acting with IB kinase, although this may require metabolism
of PGE2 to cyclopentenone derivatives by human umbilical vein
endothelial cells (55). It is curious that IL-1-induced PGE2
release occurs in tandem with increases with COX-2 mRNA
and protein, whereas exogenously added PGE2 reverses the
up-regulation. Compared with HSF, human umbilical vein en-
dothelial cells release much less PGE2 and thus COX-2 expres-
sion could not depend on PGE2 accumulation (54). The phe-
nomenon may be particular to endothelial cells since we have
observed only PGE2-dependent positive feedback in human
macrophages, chondrocytes, and skin fibroblasts.2
The present data are consistent with a more minor element
of transcriptional regulation of the COX-2 gene by IL-1
through the p38 kinase pathway occurring within the 1st hour
or so. By using nuclear run-on assays, however, others have
shown (56, 57) 5–15-fold increases in COX-2 transcriptional
rates following IL-1 stimulation which would better reflect
steady-state mRNA levels normally observed. We were able to
measure only a 2-fold increase in human COX-2 promoter
(1840 bp) activity after IL-1 stimulation of transiently
transfected HSF; addition of NS-398, PGE2, or 15-deoxy-
12,14-
prostaglandin J2 had no effect, although SB202190 was capable
of reversing promoter induction. Furthermore, MEK3 overex-
pression induced human COX-2 promoter activity to levels
similar those induced by rhIL-1, and this was also quite
sensitive to SB202190. The p38 MAP kinase pathway syner-
gized with the cAMP/PKA cascade to elicit transcriptional ac-
tivation. Saklatvala and co-workers (58) observed, using nu-
clear run-on technology and HeLa cells, that IL-1 induced a
2-fold increase in transcription of the COX-2 gene and that the
effect was refractory to inhibitors of p38 kinase. Since PGE2
incubated alone doesn’t stimulate transcription of the COX-2
gene, the massive increase and persistence of COX-2 mRNA is
most likely due, in large part, to post-transcriptional regula-
tion. Nevertheless, even considering the strong evidence for
COX-2 mRNA stabilization, one must include some transcrip-
tional control since both NS-398 and SB202190 inhibit 80–
90%, not 100%, of IL-1-induced COX-2 mRNA. Although
PGE2 stabilized COX-2 mRNA for up to 16 h in transcription-
ally arrested cells, 24 h COX-2 mRNA levels in the presence of
PGE2 were no different from controls. We attribute this to
rapid PGE2 metabolism (59, 60), an effect that would not be as
critical with cells constantly releasing PGE2 as in the presence
of IL-1 for 0–48 h (see Fig. 1).
There is some circumstantial evidence suggesting that
NF-B mediates a transcriptional induction of the COX-2 gene
by IL-1 in human RA synovial fibroblasts (25). These latter
studies, however, were not designed to address the mecha-
nisms controlling steady-state COX-2 mRNA levels and were
focused on the notion of NF-B-dependent promoter-based reg-
ulation. However, no data were reported to show a direct acti-
vation of the COX-2 reporter by NF-B via its cognate response
element(s). Evidence of this nature has been demonstrated in
osteoblasts and vascular endothelial cells, as mentioned earlier
(26, 27). Nevertheless, it could be argued that the NF-B cas-
cade acts as a “priming” mechanism in our cell cultures to
initiate transcription of the gene, while the PGE2-dependent
p38 kinase signaling pathway stabilizes, augments, and main-
tains the levels of COX-2 mRNA found in cells after an IL-1
signal. The results with TNF- may be instructive in this
regard. Consider that the TNF--induced response, in terms of
COX-2 mRNA/protein and PGE2 release, amounts to about
2.5–5% of the cellular response normally induced by IL-12; it
is not suppressed by co-incubations in the presence of NS-398,
and further additions of PGE2 potentiate the effect to the
extent that the steady-state levels of COX-2 mRNA become
indistinguishable from those generated by IL-1. In HSF,
TNF- is an extremely potent activator of the NF-B cascade
(25, 43) while having little or no discernible effect on p38
kinase. Redress to chemical blockade of IKK yielded equivocal
results and suppressed only a fraction of IL-1-induced COX-2
mRNA expression; the latter portion was not PGE2-reversible.
2
We chose to interpret these experiments with due caution as
Bay-11-7082 (IKK inhibitor) at high concentrations (2-fold
EC50) is cytotoxic as are other NF-B inhibitors especially
those that block proteosomal activity. This observation is per-
haps not surprising given that inhibition of IKK in primary and
transformed cell lines causes apoptosis (61, 62). Using stable
transfectants of HSF harboring either a wild type IB expres-
sion construct or a non-phosphorylatable IB mutant expres-
sion construct has not helped to resolve the transcriptional
issue since there was no blockade of induced COX-2 expression
by IL-1 or TNF-,2 suggesting purely post-transcriptional p38-
dependent mechanisms. In a recent publication (43), we
showed that the T-helper cell (Th2)-derived cytokines IL-4 and
IL-10 inhibit, virtually to 100%, TNF-/IL-1-stimulated
cPLA2 protein, COX-2 mRNA, COX-2 protein; and PGE2 re-
lease; tandem experiments reveal that the cytokines have no
effect on TNF-/IL-1-induced NF-B as judged by gel-shift
analysis. However, in the same study, TNF-/IL-1-induced
c/EBP activation was potently reversed by IL-4; the critical role
of c/EBP in COX-2 promoter activation has been described
previously (26, 27).
Recently it was shown (33) that the strength and duration of
COX-2 mRNA expression following IL-1 activation of HeLa
cells could be traced to the posttranscriptional regulatory
phase in which a short (123-nucleotide) fragment of the COX-2
3-UTR was shown to be essential and sufficient for the regu-
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lation of mRNA stability by a p38/MAPKAPK-2/hsp 27 cascade.
The latter nucleotide sequence interacted with a protein
identified as an AU-rich-element/poly(U) binding factor I (36).
The authors used posttranscriptional reporter constructs in
which 3-UTR fragments of COX-2 were cloned into a rabbit
-globin reporter plasmid under the control of a tetracycline
operator sequence. Dominant-negative mutants of MAP-
KAPK-2 and SB203580, a p38 inhibitor with properties similar
to SB202190, blocked the MKK3/6 expression vector stabiliza-
tion of the -globin mRNA. Others (41, 63, 64) have used
transient or stable transfections in immortalized cell lines us-
ing luciferase reporters with COX-2 3-UTR fragments cloned
downstream. Both stable and transient approaches came to the
same conclusions about the importance of the AU-rich se-
quences in the 3-UTR as targets for cytoplasmic/microsomal
binding proteins that act to destabilize mRNA. However, the
notion that mRNA stability was coupled to translational effi-
cacy was presented, and it was argued that in fact AU sequence
arrays regulate translation through a complex, yet-to-be-de-
scribed interaction of AU-binding proteins and translational
initiation factors. This notion is on solid ground based on data
with AU-rich sequences from cytokine mRNAs (48, 49).
Our work suggests that the COX-2 3-UTR inhibits protein
(reporter) translation and promotes rapid mRNA decay in HSF.
The proximal AU-rich region and distal AUUUA sequences
contribute more or less equally to the translation inhibitory
effect, although the entire 3-UTR was seemingly far more
important to mRNA decay than the AU-rich region alone. Re-
gardless, the inhibition of translation and mRNA decay were
relieved when the cells are treated with IL-1; this was a
purely PGE2/p38 MAP kinase-dependent effect that reflects
quite closely what we observed in our COX-2 mRNA experi-
ments (Fig. 6A). In contrast to the previous studies emphasiz-
ing AU-rich tract-dependent regulation (33, 36, 41), we find
that distal AUUUA sequences were quite reactive to the stabi-
lizing effects of PGE2 both in terms of mRNA and protein in
HSF. Further studies will reveal whether the eicosanoid stim-
ulates proteins that favor COX-mRNA stability (36, 50) and
translation or inhibit those that serve to destabilize the mes-
sage/translation. Whatever the case, it would not be surprising
if we find that these proteins differ in quantity and/or compo-
sition from those isolated and identified from primate cells
in heterologous systems (41) or transformed human cell lines
(e.g. HeLa, 36).
We thus used cell-permeable pharmacological inhibitors like
SB202190 and NS-398 to study COX-2 mRNA stability which
always raise concerns about specificity and thus the validity of
the data presented here. For example, SB202190 at higher
concentrations can inhibit certain isoforms of JNK (65, 66),
which could lead to erroneous conclusions about the predomi-
nant role of p38 MAP kinase. This proved not to be of concern
for us since JNK is not phosphorylated in HSF following
rhIL-1 stimulation. The issue of SB202190 inhibiting NF-B
transactivation (65) following IL-1 (or TNF-) cellular activa-
tion is probably related to cell context since, in our cell cultures,
SB202190 actually had a mild stimulatory effect in this regard.
In summary, this study describes a molecular paradigm in
which membrane phospholipid-derived metabolites, released
immediately following cytokine cellular activation, modulate cy-
tokine-target gene expression in a fundamental way. It remains
to be determined the degree to which target genes are modulated,
the type of modulation, and if the phenomenon applies to other
lipoidal metabolic pathways and/or cellular phenotypes, allowing
the development of a unifying hypothesis in this regard.
Acknowledgments—We thank Dr. K. Kiansa for excellent cell culture
work and Dr. S. Prescott for the human COX-2 promoter construct.
REFERENCES
1. Wu, K. K. (1996) J. Lab. Clin. Med. 128, 242–245
2. DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van de
Putte, L. B., and Lipsky, P. E. (1998) FASEB J. 12, 1063–1073
3. Goetzl, E. J., An, S., and Smith, W. L. (1995) FASEB J. 9, 1051–1058
4. Paul Robertson, R. (1995) Trends Endocrinol. Metab. 6, 293–297
5. Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammarstrom, S.,
and Malmsten, C. (1978) Annu. Rev. Biochem. 47, 997–1029
6. DeWitt, D. L. (1991) Biochim. Biophys. Acta 1083, 121–134
7. Picot, D., Loll, P. J., and Garavito, M. (1994) Nature 367, 243–249
8. Wang, L. H., Hajibeigi, A., Xu, X. M., Loose-Mitchell, D., and Wu, K. K. (1993)
Biochem. Biophys. Res. Commun. 190, 406–411
9. Hla, T., and Neilson, K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7384–7388
10. O’Banion, M. K., Winn, V. D., and Young, D. A. (1992) Proc. Natl. Acad. Sci.
U. S. A. 89, 4888–4892
11. Appleby, S. B., Ristima¨ki, A., Neilson, K., Narko, K., and Hla, T. (1994)
Biochem. J. 302, 723–727
12. Ryseck, R. P., Raynoscheck, C., Macdonald-Bravo, H., Dorfman, K., Mattei,
M. G., and Bravo, R. (1992) Cell Growth Differ. 3, 443–450
13. Newton, R. J., Seybold, J., Kuitert, L. M., Bergmann, M., and Barnes, P. J.
(1998) J. Biol. Chem. 273, 32312–32321
14. Dean, J. L. E., Brook, M., Clark, A. R., and Saklatvala, J. (1999) J. Biol. Chem.
274, 264–269
15. Beelman, C. A., and Parker, R. (1995) Cell 81, 179–183
16. Proudfoot, N. (1996) Cell 87, 779–781
17. Martel-Pelletier, J., Di Battista, J. A., and Lajeunesse, D. (1999) in Osteoar-
thritis: Experimental and Clinical Aspects (Reginster, J.-Y., Henrotin, Y.,
Martel-Pelletier, J., and Pelletier, J.-P., eds) pp. 156–187, Springer-Verlag,
Heidelberg
18. Crofford, L. J., Wilder, R. L., Ristimaki, A. P., Sano, H., Remmers, E. F., Epps
H. R., and Hla, T. (1994) J. Clin. Invest. 93, 1095–1101
19. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescott,
S. M. (1993) J. Biol. Chem. 268, 9049–9054
20. Rock, F. L., Hardiman, J. C., Timans, R., Kasteelin, R., and Bazan, F. J. (1997)
Proc. Natl. Acad. Sci. U. S. A. 95, 558–592
21. DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M.
(1997) Nature 388, 548–554
22. Muzio, M., Ni, J., Feng, P., and Dixit, D. V. (1997) Science 278, 1612–1615
23. Muzio, M., Natoli, G., Saccani, S., Levrero, M., and Mantovani, A. (1998) J.
Exp. Med. 187, 2097–2101
24. Zhang, F. X., Kirschning, C. J., Mancinellli, R., Xu, X.-P., Jin, Y., Faure, E.,
Mantovani, A., Rothe, M., Muziom, M., and Arditi, M. (1999) J. Biol. Chem.
274, 7611–7614
25. Crofford, L. J., Tan, B., McCarthy, C. J., and Hla, T. (1997) Arthritis Rheum.
40, 226–36
26. Schmedtje, J. F., Jr., Ji, Y. S., Liu, W. L., DuBois, R. N., and Runge, M. S.
(1997) J. Biol. Chem. 272, 601–608
27. Yamamoto, K., Arakawa, T., Ueda, N., and Yamamoto, S. (1995) J. Biol. Chem.
270, 31315–31320
28. Herlaar, E., and Brown, Z. (1999) Mol. Med. Today 5, 439–447
29. Ichijo, H. (1999) Oncogene 18, 6087–6093
30. Tibbles, L. A., and Woodgett, J. R. (1999) Cell. Mol. Life Sci. 55, 1230–1254
31. Tan, Y., Rouse, J., Zhang, A., Cariati, S., Cohen, P., and Comb, M. J. (1996)
EMBO J. 15, 4629–4642
32. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J.,
and Davis, R. J. (1995) J. Biol. Chem. 270, 7420–7426
33. Freshney, N. W., Rawlinson, L., Guesdon, F., Jones, E., Cowley, S., Hsuan, J.,
and Saklatvala, J. (1994) Cell 78, 1039–1049
34. Geng, Y., Valbracht, J., and Lotz, M. (1996) J. Clin. Invest. 98, 2425–2430
35. Guan, Z., Buckman, S. Y., Pentland, A. P., Templeton, D. J., and Morrison,
A. R. (1998) J. Biol. Chem. 273, 12901–12908
36. Lasa, M., Maktani, K. R., Finch, A., Brewer, G., Saklatvala, J., and Clark, A. R.
(2000) Mol. Cell. Biol. 20, 4265–4274
37. Di Battista, J. A., Zhang, M., Martel-Pelletier, J., Fernandes, J. C.,
Alaaeddine, N., and Pelletier, J. P. (1999) Arthritis Rheum. 42, 157–166
38. Alaaeddine, N., Di Battista, J. A., Pelletier, J. P., Cloutier, J. M., Kiansa, K.,
Dupuis, M., and Martel-Pelletier, J. (1997) J. Rheumatol. 24, 1985–1994
39. Fahmi, H., He, Y., Zhang, M., Martel-Pelletier, J., Pelletier, J.-P., and Di
Battista, J. A. (2001) Osteoarthritis Cartilage 9, 332–340
40. Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M.,
Zimmerman, G. A., White, R. L., and Prescott, S. M. (1996) Proc. Natl. Acad.
Sci. U. S. A. 93, 4816–4820
41. Dixon, D. A., Kaplan, C. D., McIntyre, T. M., Zimmerman, G. A., and Prescott,
S. M. (2000) J. Biol. Chem. 275, 11750–11757
42. Eder, J. (1997) Trends Pharmacol. Sci. 18, 319–322
43. Alaaeddine, N., Di Battista, J. A., Pelletier, J.-P., Kiansa, K., Cloutier, J.-M.,
and Martel-Pelletier, J. (1999) Arthritis Rheum. 42, 710–718
44. Di Battista, J. A., Dore´, S., Morin, N., and Abribat, T. (1996) J. Cell. Biochem.
63, 320–333
45. Morin, N., Kiansa, K., Martel-Pelletier, J., Pelletier, J.-P., and Di Battista,
J. A. (1999) Osteoarthritis Cartilage 7, Suppl. A, S21
46. Faour, W., He, Y., and Di Battista, J. A. (2000) Proceedings of the 5th World
Congress on Osteoarthritis, Barcelona, Spain, October 4–6, 2000, p. S10
(Abstr. TH030), W. B. Saunders, London
47. Gutkind, J. S. (1998) Oncogene 17, 1331–1342
48. Han, J., Brown, T., and Beutler, B. (1990) J. Exp. Med. 171, 465–475
49. Kruys, V. I., Wathelet, M. G., and Huez, G. A. (1988) Gene (Amst.) 72, 191–211
50. Dean, J. L., Wait, R., Mahtani, K. R., Sully, G., Clark, A. R., and Saklatvala,
J. (2001) Mol. Cell. Biol. 21, 721–730
51. Mestre, J. R., Mackrel, P. J., Rivadeneira, D. E., Stapleton, P. P., Tanabe, T.,
and Daly, J. M. (2000) J. Biol. Chem. 275, 3977–3982
52. He, W., Pelletier, J. P., Martel-Pelletier, J., Di Battista, J. A., (2001) Arthritis
Rheum., in press
PGE2 Regulates COX-2 mRNA Stability and Translation31730
53. Akarasereenont, P., Tachatrisak, K., Chotewuttakorn, S., and Thaworn, A.
(1999) Mediat. Inflamm. 8, 287–294
54. Callejas, N. A., Castrillo, A., Bosca, L., and Martin-Sanz, P. (1999) J. Phar-
macol. Exp. Ther. 288, 1235–1241
55. Rossi, A., Kapahl, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and
Gabriella Santoro, M. (2000) Nature 403, 103–107
56. Newton, R., Kuitert, L., Bergmann, M., Adcock, I., and Barnes, P. (1997)
Biochem. Biophys. Res. Commun. 237, 28–32
57. Ristimaki, A., Garfinkel, S., Wessendorf, J., Maciag, T., and Hla, T. (1994)
J. Biol. Chem. 269, 11769–11775
58. Ridley, S. H., Dean, J. L. E., Sarsfield, S. J., Brook, M., Clark, A. R., and
Saklatvala, J. (1998) FEBS Lett. 439, 75–80
59. Oliw, E. H. (1989) Biochim. Biophys. Acta 1001, 107–110
60. Oliw, E. H., Fahlstadius, P., and Hamberg, M. (1986) J. Biol. Chem. 261,
9216–9221
61. Wang, C. Y., Mayo, M. W., and Baldwin, A. S. (1998) Science 274, 786–787
62. Karin, M., and Delhase, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9067–9069
63. Newton, R., Seybold, J., Liu, S. F., and Barnes, P. (1997) Biochem. Biophys.
Res. Commun. 234, 85–89
64. Gou, Q., Liu, C. H., Ben-Av, P., and Hla, T. (1998) Biochem. Biophys. Res.
Commun. 242, 508–512
65. Wesselborg, S., Bauer, M. K. A., Vogt, M., Schmitz, M. L., and Schulze-Osthoff,
K. (1997) J. Biol. Chem. 272, 12422–12429
66. Clerk, A., and Sugden, P. H. (1997) FEBS Lett. 426, 93–96
PGE2 Regulates COX-2 mRNA Stability and Translation 31731
